Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huaweiyi probiotics
- Development stage
- Unknown
- Lead developer
- The Second People's Hospital of Neijiang
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Huaweiyi probiotics (also referred to by the code name BP-1) is a microbial therapy being investigated for the prevention and management of opioid-induced gastrointestinal side effects (OIGS), such as constipation, nausea, and vomiting. It is specifically being studied in patients with solid tumors who are experiencing cancer pain and receiving morphine treatment. The formulation works by modulating the gut microbiota to counteract the dysbiosis and intestinal motility issues typically caused by opioid analgesics. A prospective, multicenter, randomized, double-blind, parallel-controlled Phase 2 clinical trial (ChiCTR2200057262) has been initiated by The Second People's Hospital of Neijiang to evaluate its efficacy and safety in this patient population.
- Brand names
- Huaweiyi
- Other names
- Huaweiyi probiotics
Beyond the preview
Go deeper on Huaweiyi probiotics.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Huaweiyi probiotics.